|0.3900||+0.0050||+1.30%||Vol 521.26K||1Y Perf -55.86%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||0.01 2.05%|
|Target Price||9.00||Analyst Rating||Hold 3.00|
|Potential %||2.21K||Finscreener Ranking||★+ 43.58|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★ 40.22|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★ 34.59|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||19.05||Earnings Rating||Buy|
|Market Cap||14.32M||Earnings Date||30th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||30th Mar 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||806.65K|
|Avg. Monthly Volume||549.31K|
|Avg. Quarterly Volume||664.60K|
Chembio Diagnostics Inc. (NASDAQ: CEMI) stock closed at 0.39 per share at the end of the most recent trading day (a 1.3% change compared to the prior day closing price) with a volume of 521.26K shares and market capitalization of 14.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 324 people. Chembio Diagnostics Inc. CEO is Richard L. Eberly.
The one-year performance of Chembio Diagnostics Inc. stock is -55.86%, while year-to-date (YTD) performance is 77.51%. CEMI stock has a five-year performance of -95.06%. Its 52-week range is between 0.19 and 1.24, which gives CEMI stock a 52-week price range ratio of 19.05%
Chembio Diagnostics Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.56, a price-to-sale (PS) ratio of 0.26, a price to cashflow ratio of 649.30, a PEG ratio of 2.32, a ROA of -54.60%, a ROC of -62.04% and a ROE of -124.72%. The company’s profit margin is -57.27%, its EBITDA margin is -53.00%, and its revenue ttm is $39.18 Million , which makes it $1.07 revenue per share.
Of the last four earnings reports from Chembio Diagnostics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Chembio Diagnostics Inc.’s next earnings report date is 30th Mar 2023.
The consensus rating of Wall Street analysts for Chembio Diagnostics Inc. is Hold (3), with a target price of $9, which is +2 207.69% compared to the current price. The earnings rating for Chembio Diagnostics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chembio Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Chembio Diagnostics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.03, ATR14 : 0.02, CCI20 : -49.72, Chaikin Money Flow : 0.06, MACD : -0.01, Money Flow Index : 54.42, ROC : -12.67, RSI : 45.63, STOCH (14,3) : 55.16, STOCH RSI : 1.00, UO : 40.94, Williams %R : -44.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chembio Diagnostics Inc. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Chembio Diagnostics Inc is a US-based company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
CEO: Richard L. Eberly
Telephone: +1 631 924-1135
Address: 555 Wireless Boulevard, Hauppauge 11788, NY, US
Number of employees: 324
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.